Results 51 to 60 of about 2,133 (164)

Characterization of Prurigo Nodules in Adults With Moderate‐To‐Severe Atopic Dermatitis in Japan: A 2‐Year Observational Study

The Journal of Dermatology, Volume 53, Issue 8, Page 1099-1114, August 2026.
ABSTRACT Clinical phenotypes of atopic dermatitis (AD) can vary, with some individuals displaying difficult‐to‐treat prurigo nodularis‐like lesions. We aimed to assess the real‐world disease burden and treatment course of Japanese adults with AD‐associated prurigo nodules (AD‐Pn) receiving conventional AD treatments.
Yoko Kataoka, Takafumi Etoh, Hidehisa Saeki, Norito Katoh, Satoshi Teramukai, Yuki Tajima, Kwinten Bosman, Marius Ardeleanu, Kazuhiko Arima   +8 more
wiley   +1 more source

Dupilumab's Real‐World Efficacy and Safety Across Age Groups for Children and Adolescents With Paediatric Atopic Dermatitis

Australasian Journal of Dermatology, Volume 67, Issue 5, Page 301-308, August 2026.
ABSTRACT Background/Objectives Dupilumab is an anti‐interleukin (IL)‐4 receptor (IL‐4Rα) monoclonal antibody used to manage atopic dermatitis (AD). There is a paucity of real‐world Australian data for dupilumab in paediatric AD, especially regarding differences in clinical profiles between age groups.
Paul Sun Woo Kim, Jacqueline Tu, Kelvin Truong, Gloria Fong, William Luu, Peter Barclay, Melanie Wong, Li‐Chuen Wong   +7 more
wiley   +1 more source

Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema

Allergy, Volume 81, Issue 8, Page 2815-2832, August 2026.
This study performed an unbiased molecular profiling of CHE patients across diverse etiologies to identify shared pathogenic drivers and evaluate the impact of IL‐4Rα blockade via dupilumab over 16 weeks. CHE shows a mixed immune signature involving type 1, 2, and 3 pathways with features of atopic dermatitis and psoriasis.
Perrine Gery, Rüçhan Ekren, Emilie Bérard, Aurélie Du‐Thanh, Hugo Rimet, Fatma Jendoubi, Vanina Lenief, Nadia Raison‐Peyron, Amel Bouznad, Maria P. Konstantinou, Jonathan Rioual, Lilian Basso, Juliette Mouiren, Manon Boussier, Brigitte Milpied, Cristina Bulai Livideanu, Louise Jaulent, Florence Hacard, Marine A. Lefevre, Audrey Nosbaum, Julien Seneschal, Marc Vocanson, Carle Paul, Nicolas Gaudenzio, Marie Tauber, on behalf of the French Atopic Dermatitis Network from de GREAT Research group   +25 more
wiley   +1 more source

Dupilumab‐Induced Psoriasis in a Patient with Bullous Pemphigoid

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Nina Matthes, Julian Kött, Finn Abeck, Inga Hansen‐Abeck, Jana Bertels, Nina Booken, Stefan W. Schneider   +6 more
wiley   +1 more source

OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 8, Page 1318-1331, August 2026.
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta, Julia Steriopoulos, Vasiliki Economopoulos, Paradi Mirmirani, Vincent Piguet   +4 more
wiley   +1 more source

Nemolizumab for Pruritus Control in Cutaneous T‐Cell Lymphoma: A Case Series

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Yenny Angela, Ralf Gutzmer, Rudolf Stadler   +2 more
wiley   +1 more source

Broadening the View: Substance P and Its Metabolism in Pruritus‐Related Diseases

The Journal of Dermatology, Volume 53, Issue 7, Page 967-979, July 2026.
ABSTRACT Chronic pruritus is a debilitating symptom accompanying numerous inflammatory skin diseases and remains a major therapeutic challenge. Neurogenic inflammation plays a central role in its pathogenesis, with the tachykinin substance P acting as a key mediator at the interface of the nervous system, immune cells, and cutaneous tissues.
Thomas Walter, Bjoern B. Burckhardt
wiley   +1 more source

Prurigo Nodularis [PDF]

JAMA Dermatology, 2022
openaire   +2 more sources

Patch Test Results With the European Baseline Series, 2021/2022—Joint European Results of the ESSCAA and the EBSB Working Groups of the ESCD, and the GEIDACC

Contact Dermatitis, Volume 95, Issue 1, Page 17-32, July 2026.
ABSTRACT Background Patch test results obtained with the European Baseline Series (EBS) in its current version serve both contact allergy surveillance and (re‐)assessing the diagnostic value of EBS allergens. Objectives To present results of current EBS patch testing, obtained in 59 departments in 14 European countries during 2021 and 2022.
Wolfgang Uter, S. Mark Wilkinson, Olivier Aerts, Andrea Bauer, Leopoldo Borrego, Richard Brans, Timo Buhl, Heinrich Dickel, Aleksandra Dugonik, Francesca Larese Filon, Ana Giménez Arnau, Cataldo Patruno, Györgyi Pónyai, Stamatis Gregoriou, Steffen Schubert, Dagmar Simon, Luca Stingeni, Skaidra Valiukevičienė, Elke Weisshaar, Thomas Werfel, Margarida Gonçalo, Marie‐L. A. Schuttelaar, ESSCAA and EBSB ESCD Working Groups, and the GEIDACC , Birger Kränke, Alexander Navarini, Philip Spring, Ulrike Beiteke, Cecilia Dietrich, Sibylle Schliemann, Detlef Becker, Swen Malte John, Nicola Wagner, Dimitra Koumaki, Maddalena Napolitano, Anna Belloni Fortina, Francesca Larese Filon, Rosella Gallo, Thomas Rustemeyer, Radoslaw Spiewak, Maja Kalac Pandurovic, Tanja Kmecl, Mojca Simončič Godnič, Nada Kecelj, Philippa Cousen, Ella Dendooven, Juan Francisco Silvestre Salvador, José Manuel Carrascosa Carrillo, Mónica Munera Campos, Esther Serra Baldrich, Gemma Melé‐Ninot, Cristina Barrabés Torrella, David Pesqué, María Antonia Pastor Nieto, Francisco Navarro Triviño, Inmaculada Ruiz Gonzales, Enrique Gómez de la Fuente, Susana Córdoba Guijarro, Francisco Javier Ortiz de Frutos, Fátima Tous Romero, Tatiana Sanz Sánchez, Pablo Chicharro Manso, Marta Andreu Barasoain, Marta Elosua González, Araceli Sánchez Gilo, Paloma Sánchez‐Pedreño Guillén, Pedro Mercader‐García, Carmen Paredes Suárez, María Elena Gatica Ortega, José Juan Pereyra Rodríguez, Javier Miquel Miquel, Mercedes Rodríguez Serna, Violeta Zaragoza Ninet, Ricardo González Pérez   +73 more
wiley   +1 more source

New‐Onset Vitiligo During Dupilumab Treatment: A Clinical Observation and Literature Review

The Clinical Respiratory Journal, Volume 20, Issue 7, July 2026.
Dupilumab rarely induces new‐onset vitiligo, even after discontinuation of the drug, potentially through the activation of the Th1/IFN‐γ pathway following IL‐4R blockade. Female sex and the use of topical corticosteroids are associated with improved outcomes, whereas discontinuing dupilumab alone does not ensure repigmentation.
Xuhui Pu, Suzhen Ju, Yanfang Yu
wiley   +1 more source